The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD

NCT ID: NCT03679312

Last Updated: 2024-01-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 140 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-09-04
• Study Completion Date: 2023-11-20

Brief Summary

Chronic Obstructive Pulmonary Disease (COPD) is a lung disorder commonly caused by smoking, which makes breathing more difficult. When COPD patients exercise, they are not efficient breathers and this leads to serious breathing difficulties, which often causes these patients to stop exercise at low intensities. Even though patients with a mild form of COPD have relatively well preserved lung function, they still have inefficient breathing during exercise. The investigators think that these patients have problems exchanging fresh gas (i.e., oxygen) into the blood stream because of poor lung blood vessel function. The investigators will test whether inhaled medications, specifically nitric oxide, can improve lung blood vessel function and decrease breathing difficulties during exercise. With this research, the investigators will understand more about breathing efficiency and lung blood vessel function in patients with COPD, and find out whether improving lung blood vessel function helps COPD patients breathe easier and exercise longer. Understanding the reasons behind the feeling of difficult breathing may lead to more effective therapy and improved quality of life in COPD patients.

Detailed Description

Chronic Obstructive Pulmonary Disease (COPD) is a respiratory disorder typically caused by smoking and is characterized by airway obstruction. Exertional dyspnea (perceived breathlessness) is a hallmark of COPD regardless of severity and is the primary reason for exercise intolerance even in patients with mild COPD (defined using spirometric criteria as a forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.70 and a FEV1 ≥ 80%). Dyspnea in COPD has been shown to profoundly reduce patient quality of life, physical activity, and impair patients' ability to complete day-to-day tasks. Previous work in mild COPD has demonstrated that exertional dyspnea is the result of increased work of breathing during exercise, and that this increased work of breathing comes from: 1) an exaggerated ventilatory response to exercise (i.e. increased minute ventilation relative to carbon dioxide production, V̇E/V̇CO2), and 2) airflow limitation (i.e. expiratory flow limitation and resulting dynamic hyperinflation). A great deal of work has focused on improving airflow limitation in COPD; however, very little has been done to understand and treat the exaggerated ventilatory response to exercise in COPD.

Several previous studies in COPD have consistently shown an elevated ventilatory response (i.e. greater V̇E/V̇CO2) during exercise. The elevated V̇E/V̇CO2 response to exercise appears to be clinically important, as it independently predicts mortality in COPD and indicates that physiological abnormalities beyond airflow obstruction are important in determining disease severity, dyspnea, and risk of death. This increased V̇E/V̇CO2 in COPD appears to be secondary to increased deadspace ventilation(i.e. sections of the lung with ventilation, but no perfusion), and this increased deadspace ventilation results in a compensatory increase in total minute ventilation (i.e. increased V̇E/V̇CO2) to maintain effective alveolar ventilation and arterial blood gas homeostasis.

The underlying mechanism(s) for the increased deadspace ventilation and V̇E/V̇CO2 during exercise in mild to moderate COPD is currently unclear; however, pulmonary microvascular abnormalities and hypoperfusion of pulmonary capillaries are potential pathophysiologic mechanisms. Mild to moderate COPD patients have reduced pulmonary microvascular blood flow in nonemphysematous lung regions, which has led researchers to conclude that the low pulmonary perfusion in an intact pulmonary vascular bed is likely the result of pulmonary vascular dysfunction. Ventilation-perfusion (V̇A/Q̇) data in mild and moderate COPD shows substantial V̇A/Q̇ inequality at rest, with the V̇A/Q̇ distribution skewed towards regions of high V̇A/Q̇, which is indicative of increased deadspace. Consistent with this capillary hypoperfusion hypothesis, our recent work has shown a blunted pulmonary capillary blood volume response to exercise in mild COPD, when compared to age- and height-matched non-smoking controls. Importantly, the low pulmonary capillary blood volume was associated with increased V̇E/V̇CO2 during exercise, suggesting that low pulmonary perfusion (i.e. reduced pulmonary capillary blood volume) leads to increased deadspace.

Inhaled nitric oxide (NO) is commonly used to test for pulmonary vasodilatory responses in patients with pulmonary arterial hypertension (PAH), as it increases NO bioavailability and improves pulmonary vascular function. Previous work in PAH and heart failure (HF) patients has shown that standard doses (20-40 parts per million (ppm)) of inhaled NO can reduce pulmonary vascular resistance and increase peak oxygen consumption (V̇O2peak). If inhaled NO can reduce vascular dysfunction and increase perfusion in mild and moderate COPD, this would result in a reduction in V̇E/V̇CO2 and improved exercise tolerance.

STUDY PURPOSE

Purpose: To examine the effect of inhaled NO on exercise capacity (V̇O2peak) ventilation and dyspnea in in patents with COPD.

Hypothesis: Inhaled NO will improve exercise capacity, secondary to reduced V̇E/V̇CO2 and dyspnea, in mild and moderate COPD, while no change will be observed in healthy controls and severe COPD.

Study Design: Randomized double-blind cross-over design.

All participants will have a pulmonary function and cardiopulmonary exercise test. The study procedure is briefly outlined below and is further outlined in the attached University Hospital Foundation Grant.

Study Protocol: Seven sessions will be completed over a 3-week period in the following order:

Day 1) Participant enrollment, medical history, standard pulmonary function (PFT) and cardiopulmonary exercise test (CPET).

Days 2 & 3) Randomly-ordered experimental CPETs while either breathing room air or inhaled nitric oxide (room air with 40 ppm NO).

Days 4 & 5) Randomly-ordered constant load exercise tests, at 75% peak power output, while either breathing room air or inhaled nitric oxide (room air with 40 ppm NO).

Day 6) Ultrasonography doppler measurements will be completed to determine pulmonary arterial systolic pressure (at rest and during exercise) while breathing room air or inhaled nitric oxide. Doppler measurements of systemic vascular endothelial function will be measured at rest while breathing room air. To enhance doppler signal during the cardiac ultrasound, agitated saline contrast will be used. A small sample of venous blood will be taken to analyze inflammatory levels. Additionally, participants will breathe into a small tube so that expelled saliva can be analyzed to determine airway inflammation.

Day 7) Prospective quantitative computed tomography (CT) imaging will be completed to obtain lung density, heterogeneity, tissue, vascular and airway measurements.

Each visit will take approximately 3 hours. The total time duration for each participant will be approximately 21 hours.

Conditions

Dyspnea

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

COPD Group

COPD to receive either placebo or inhaled nitric oxide (40ppm)

Group Type: EXPERIMENTAL

Nitric Oxide

Intervention Type: DRUG

Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

Placebo

Intervention Type: DRUG

Inhaled placebo, which consists of breathing medical grade air (21% O2).

Control Group

Control group to receive either placebo or inhaled nitric oxide (40ppm)

Group Type: EXPERIMENTAL

Nitric Oxide

Intervention Type: DRUG

Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

Placebo

Intervention Type: DRUG

Inhaled placebo, which consists of breathing medical grade air (21% O2).

Interventions

Nitric Oxide

Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

Intervention Type: DRUG

Placebo

Inhaled placebo, which consists of breathing medical grade air (21% O2).

Intervention Type: DRUG

Other Intervention Names

Inhaled Nitric Oxide; Medical Grade Room Air

Eligibility Criteria

Inclusion Criteria

• No significant cardiovascular disease.
• No significant metabolic disease
• No significant neuromuscular disease
• Participants will range from 18-85 years old

• Age- and sex-matched to COPD patients
• Normal lung function
• Minimal smoking history
• No previous diagnosis of COPD
• Participants will range from 18-85 years old

Exclusion Criteria

• Individuals with significant cardiovascular, metabolic, neuromuscular or any other disease
• Individual with musculoskeletal injuries
• Individuals currently on oral steroids (i.e. prednisone), phosphodiesterase type 5 (PDE5) inhibitors or supplemental O2 therapy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Hospital Foundation

OTHER

Sponsor Role: collaborator

Canadian Lung Association

INDUSTRY

Sponsor Role: collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role: collaborator

University of Alberta

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael K Stickland, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Locations

Clinical Sciences Building

Edmonton, Alberta, Canada

Countries

Canada

Other Identifiers

Pro00078715

Identifier Type: -

Identifier Source: org_study_id